1
Return

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis

delete2026-03-11
delete0
delete
OA
AI
S
Stephan A. Kaeser
S
Stephanie A. Schultz
A
Anna Hofmann
L
Lisa M. Häsler
Y
Ying Xu
M
Marius Lambert
U
Ulrike Obermüller
K
Kathrin Brockmann
J
Johan Bijzet
H
Hans Nienhuis *
M
Mario Nuvolone
L
Laura Obici
G
Giovanni Palladini *
U
Ute Hegenbart
S
Stefan Schönland *
M
Mathias Jucker *
DOI:10.1038/s41591-026-04272-2delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Elevated blood levels of phosphorylated tau (p-tau) are diagnostic of Alzheimer disease and are associated with the deposition of amyloid-β in the cerebral neuropil. Elevated p-tau levels have also been associated with cerebral deposition of Danish amyloid and prion protein amyloid. Here we analyzed p-tau in serum from four different cohorts of people with the most common types of systemic amyloidosis, transthyretin (ATTR) amyloidosis and immunoglobulin light chain (AL) amyloidosis. We found higher levels of serum p-tau181 in the AL and ATTR groups than in controls. Subsequent analyses revealed that these effects were more pronounced in the presence of polyneuropathy (PNP) and in AL compared to ATTR amyloidosis. Individuals with different forms of PNP that were not due to amyloidosis did not exhibit elevated p-tau181 levels. In cases of presymptomatic (genetic) ATTR, p-tau181 levels increased as a function of predicted years from symptom onset. Additional measurement of p-tau217 in one cohort revealed similar increases, and discriminated people with AL and those with ATTR from controls equally as well as p-tau181. These findings suggest that elevated serum p-tau levels are not specific to Alzheimer disease and may also serve as a diagnostic tool of ATTR and AL amyloidosis, with potential utility in distinguishing amyloidosis-related PNP from PNP of other etiologies. Elevated serum levels of phosphorylated tau are not specific to Alzheimer’s disease and may also serve as a diagnostic tool for the most common types of systemic amyloidosis, with potential utility in distinguishing amyloidosis-related polyneuropathy from polyneuropathy of other etiologies.
Keywords:
Biomarkers
Neuroscience
Biomedicine
general
Cancer Research
Metabolic Diseases
Infectious Diseases
Molecular Medicine
Neurosciences
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Nature Medicine cover
Nature Medicine
IF:
50
Papers:
1.4W
Citations:
13.4W

Organization

U
university medical center groningen
Scholars:
419
Papers: 183
Citations: 0
H
Harvard University
Scholars:
26.2W
Papers: 21.9W
Citations: 28.7W
U
university heidelberg
Scholars:
125
Papers: 46
Citations: 0
U
university of pavia
Scholars:
2.0W
Papers: 1.6W
Citations: 8
I
irccs fondazione policlinico san matteo
Scholars:
9
Papers: 6
Citations: 0
U
university medical centre groningen
Scholars:
97
Papers: 46
Citations: 0
G
german center for neurodegenerative diseases
Scholars:
500
Papers: 130
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers